These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives. Vos M; Sleijfer S Eur J Cancer; 2018 Jan; 88():87-91. PubMed ID: 29202389 [TBL] [Abstract][Full Text] [Related]
5. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Bui-Nguyen B; Butrynski JE; Penel N; Blay JY; Isambert N; Milhem M; Kerst JM; Reyners AK; Litière S; Marréaud S; Collin F; van der Graaf WT; Eur J Cancer; 2015 Jul; 51(10):1312-20. PubMed ID: 25912752 [TBL] [Abstract][Full Text] [Related]
6. Trabectedin's contribution to the treatment of sarcomas. Blay JY Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729 [TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437 [TBL] [Abstract][Full Text] [Related]
8. Current questions in soft tissue sarcoma: further steps with Yondelis®. Reichardt P Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):25-30. PubMed ID: 23638728 [TBL] [Abstract][Full Text] [Related]
9. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N; Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439 [TBL] [Abstract][Full Text] [Related]
10. Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. Martin-Broto J; Pousa AL; de Las Peñas R; García Del Muro X; Gutierrez A; Martinez-Trufero J; Cruz J; Alvarez R; Cubedo R; Redondo A; Maurel J; Carrasco JA; López-Martin JA; Sala Á; Meana JA; Ramos R; Martinez-Serra J; Lopez-Guerrero JA; Sevilla I; Balaña C; Vaz Á; De Juan A; Alemany R; Poveda A J Clin Oncol; 2016 Jul; 34(19):2294-302. PubMed ID: 27185843 [TBL] [Abstract][Full Text] [Related]
11. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers. Van Tine BA; Trent JC Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922 [TBL] [Abstract][Full Text] [Related]
12. Role of palliative chemotherapy in advanced epithelioid sarcoma. Jones RL; Constantinidou A; Olmos D; Thway K; Fisher C; Al-Muderis O; Scurr M; Judson IR Am J Clin Oncol; 2012 Aug; 35(4):351-7. PubMed ID: 21422990 [TBL] [Abstract][Full Text] [Related]
13. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Blay JY; von Mehren M; Samuels BL; Fanucchi MP; Ray-Coquard I; Buckley B; Gilles L; Lebedinsky C; Elsayed YA; Le Cesne A Clin Cancer Res; 2008 Oct; 14(20):6656-62. PubMed ID: 18927308 [TBL] [Abstract][Full Text] [Related]
14. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Kawai A; Araki N; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Tanase T; Hasegawa T; Takahashi S Lancet Oncol; 2015 Apr; 16(4):406-16. PubMed ID: 25795406 [TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin. Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704 [TBL] [Abstract][Full Text] [Related]
17. [High-dose chemotherapy in soft tissue sarcomas of adults]. Ray-Coquard I; Biron P; Blay JY Bull Cancer; 2001 Sep; 88(9):858-62. PubMed ID: 11604358 [TBL] [Abstract][Full Text] [Related]
18. Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review. Pang A; Carbini M; Maki RG JAMA Oncol; 2016 Jul; 2(7):941-7. PubMed ID: 27148906 [TBL] [Abstract][Full Text] [Related]
19. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt? Le Cesne A Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726 [TBL] [Abstract][Full Text] [Related]
20. Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study. Angarita FA; Cannell AJ; Abdul Razak AR; Dickson BC; Blackstein ME BMC Cancer; 2016 Jan; 16():30. PubMed ID: 26786213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]